Ascletis Doses First Patient in Phase III Trial for Oral Weight-Loss Drug
Biotech company Ascletis has administered the first dose to a participant in its global Phase III clinical trial for ASC30, an experimental oral medication designed for chronic weight management. The milestone advances development of a once-daily GLP-1 receptor agonist alternative to injectable treatments.